Wei Li

Dr. Wei Li


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 November 2023 in European Journal of Clinical Microbiology & Infectious Diseases
Verified
Journal Article
Open access
PDF file
JGJian Guo
Jian Guo
CXChenlu Xiao
Chenlu Xiao
WTWenjie Tian
Wenjie Tian
LLLi Lv
Li Lv
LHLiang Hu
Liang Hu
WWWenjuan Wu
Wenjuan Wu
Purpose: The objective of this multicenter study was to compare the diagnostic performance of lateral flow assay (LFA) and enzyme-linked immunosorbent assay (ELISA) to detect the Dynamiker Aspergillus Galactomannan levels in serum and bronchoalveolar lavage fluid (BALF) samples for I. Methods: We registered 310 clinically suspected Aspergillus infection patients from December 2021 to February 2023 and classified them into subgroups as the “IA group” and “non-IA group” based on the latest EORTC/MSG guidelines. The immunoassays were analyzed by LFA and ELISA respectively. Results: Galactomannan was examined using LFA, and serum and BALF samples demonstrated sensitivities of 82.57% and 89.47%, specificities of 90.76% and 92.00%, PPVs of 89.11% and 96.23%, and NPVs of 85.04% and 79.31%, respectively. Galactomannan was observed using two assays in serum and BALF samples and showed PPAs of 95.11% and 93.33%, NPAs of 89.19% and 96.30%, and TPAs of 92.47% and 94.25%, respectively. The ROC curve demonstrated that LFA had optimum diagnostic value when the index value (I value) = 0.5, the sensitivity was 84.94%, and the specificity was 90.97%. Conclusion: Compared to the ELISA method, the LFA has shown excellent performance for the diagnosis of IA in serum and BALF sample and can be used as an assay for the early diagnosis of patients with IA. The dynamic change in galactomannan levels may be useful for assessing treatment response.

11 July 2026 in Journal of Infection
Verified
Journal Article
Open access
FHFuyao Hu
Fuyao Hu
ZYzhang yi
zhang yi
MHMingju Hao
Mingju Hao
WLWei Li
Wei Li
Hypervirulent carbapenem-resistant Klebsiella pneumoniae (hv-CRKP) exhibiting cross-resistance to multiple antimicrobial agents represents a formidable therapeutic challenge. Therefore, elucidating the mechanisms driving antimicrobial resistance is crucial. A ceftazidime-avibactam-resistant K. pneumoniae isolate was recovered and subjected to antimicrobial susceptibility testing and whole-genome sequencing. Resistance mechanisms were investigated through gene cloning and enzymatic kinetic assays. Public NCBI databases were interrogated to determine the prevalence of multicopy blaKPC genes. Growth curves and plasmid stability assays were performed to evaluate the fitness costs. An hv-CRKP isolate harboring two IS26-mediated copies of blaKPC-14 was identified following prolonged ceftazidime-avibactam therapy. The strain displayed high-level resistance to ceftazidime-avibactam, cefiderocol, and aztreonam-avibactam without appreciable fitness cost. Throughout treatment, the critically ill patient exhibited a persistently elevated estimated glomerular filtration rate. Comparative plasmid analysis demonstrated that IS26-mediated tandem duplication was widespread among plasmids carrying multiple copies of blaKPC. Selective pressure from prolonged ceftazidime-avibactam therapy, with potential contributions from host-related factors affecting antimicrobial exposure, could facilitate the emergence of blaKPC variants and consequently promote cross-resistance. Dual-copy blaKPC substantially increased resistance levels without imposing a significant fitness burden. These findings underscore the value of timely genomic surveillance and antimicrobial susceptibility testing for optimizing antimicrobial therapy.

11 November 2026 in Frontiers in Microbiology
Verified
Journal Article
Open access
PDF file
YZYuxiao Zhao
Yuxiao Zhao
YGYiwen Gao
Yiwen Gao
SWShixuan Wei
Shixuan Wei
WSWeiwei Sun
Weiwei Sun
XZXiaoli Zhang
Xiaoli Zhang
WLWei Li
Wei Li
Mycobacterium wolinskyi is an emerging rapidly growing nontuberculous mycobacterium increasingly recognized as a cause of skin, soft-tissue, and device-associated infections, including infections in immunocompetent individuals. However, its genomic characteristics and interactions with host immune cells remain poorly understood. In this study, we characterized a clinical M. wolinskyi isolate, designated QL01, recovered from a facial skin infection in an 11-year-old child, by combining antimicrobial susceptibility testing, whole-genome sequencing, comparative genomic analysis, and macrophage infection assays with transcriptomic profiling. QL01 was resistant to clarithromycin, imipenem, and trimethoprim-sulfamethoxazole, while remaining susceptible to amikacin, linezolid, moxifloxacin, minocycline, and doxycycline. Whole-genome sequencing generated a complete circular chromosome and identified antimicrobial resistance-associated homologs and host interaction-associated homologs. Comparative analysis revealed variable conservation of type VII secretion system (T7SS)- and Mce-associated loci among representative rapidly growing mycobacteria. Following uptake by mouse bone marrow-derived macrophages, viable intracellular QL01 remained recoverable after 24 h. RNA sequencing revealed an early innate immune and pro-inflammatory transcriptional response, with enrichment of TNF, NF-κB, Toll-like receptor, and C-type lectin receptor signaling pathways. RT-qPCR further confirmed increased expression of Ccl2 , Tnf , Il1b , Tlr2 , Clec4e , and Tnfaip3 . ELISA confirmed increased secretion of TNF-α, IL-1β, and IFN-β. Inhibition of IKK/NF-κB signaling attenuated QL01-induced phosphorylation of p65 and IκBα and reduced inflammatory cytokine secretion. These findings characterize the genomic features of a clinical M. wolinskyi isolate and describe the early macrophage response to this emerging nontuberculous mycobacterial species.